MGI Tech has collaborated with Oncoclínicas&Co, through OC Medicina de Precisão, which comprises Genomics, Pathology and Big Data laboratories, to expand access to cutting-edge genomic tests and strengthen diagnostic capabilities in the field of oncology in Brazil.

The challenge of tackling cancer is increasing significantly in the country. According to a study conducted by the Federal University of São Paulo (UNIFESP), cancer-related mortality has overtaken that of cardiovascular diseases in 727 Brazilian cities.

This research, published by the scientific magazine The Lancet Regional Health – Americas, analyzed death causes across Brazil's 5,570 municipalities over a 19-year period. So, monitoring neoplasms is essential to detect the disease at an early stage and increase the effectiveness of treatments, allowing for more positive clinical outcomes.

The main objective of the agreement is, therefore, to enable technological solutions that reduce costs, speed up diagnostic processes and promote faster and more accurate therapeutic decisions. These advances will contribute to a more efficient and equitable healthcare system, benefiting patients and professionals in the field.

"Genomics is transforming the way we understand and treat cancer, and this partnership is a major milestone for oncology in Brazil because it helps raise awareness among patients and professionals about the positive impact of oncogenetics on health promotion, possibilities and benefits of a more precise and personalized medicine, to facilitate the access to advanced technologies and to expand genetic diagnostic capacity", explained Carlos Carpio, Senior Commercial Director for MGI Latin America and General Manager for Brazil.

"This strategic partnership with MGI accelerates the laboratory advancements in genomic medicine. By leveraging cutting-edge technology and expert support, our laboratory can significantly enhance productivity, reduce operational costs, and generate higher-quality data. This collaborative approach empowers our laboratory to offer faster, more accurate diagnostic testing, ultimately improving patient outcomes and accelerating the development of personalized treatments", said Fernanda Koyama, Manager of Genomics and R&D in OC Medicina de Precisão at Oncoclínicas&Co.

The Oncoclínicas&Co has now another advanced technology for cancer diagnosis with the addition of the medium-throughput DNBSEQ-G400 genomic sequencer. Based on MGI's DNBSEQ technology, it can complete the sequencing process rapidly and enable researchers to detect genetic predispositions to cancer and identify specific gene mutations and determine effective oncology treatment through comprehensive genetic profiling of tumors.

The new technology is available at Oncoclínicas&Co in São Paulo. In 2024, approximately one thousand samples were sequenced per month in the institution's Genomics department, totaling around 12,000 samples for the year. Of these, 60 percent are germline panels for the diagnosis of cancer syndromes and 40 percent are somatic panels, focused on therapeutic decisions based on genomic biomarkers.

"Over the past two years, OC Medicina de Precisão has been relentlessly investing in process efficiency and the adoption of technologies that allow us to become increasingly competitive—serving a growing number of private patients, strengthening and expanding partnerships with pharmaceutical companies, and being the first choice for health insurers when it comes to precision medicine. In this way, we contribute to expanding public access to cutting-edge medicine and ensuring the sustainability of the healthcare system," highlighted Rodrigo Alvarenga, Operations Executive at Oncoclínicas&Co.